All enrolled patients were on bone-targeting agents at study entry, and it has been shown in vitro that bone-targeting agents (including clodronate, pamidronate and zoledronic acid) can inhibit tumor cell expression of MMP2 and MMP9 [43]. Here, MMP2 is linked to neoplasm.